Aquestive Therapeutics, Inc.

Aquestive Therapeutics, Inc.(AQST)资讯与事件

$5.020

-0.136 (-2.71%)收盘时

AQST 资讯

AQST 事件

8/11 16:30

Aquestive Therapeutics Q2 Revenue $13.82M Beats Expectations

Reports Q2 revenue $13.82M, consensus $11.56M. "The epinephrine rescue market continues to grow and remains available for conversion from older medical device technology including autoinjectors," said Daniel Barber, President and Chief Executive Officer of Aquestive Therapeutics. "As we bring Anaphylm to market, if approved by the FDA, we believe we can be instrumental in driving conversion in the allergist office and, ultimately, the broader market. As we prepare to resubmit our application to the FDA in the coming weeks, our full attention will be to prepare for a focused, allergist-first launch of Anaphylm as quickly as possible, if approved by the FDA. In the meantime, our medical affairs team continues to interact with the allergy community on a daily basis."

8/11 16:30

AQST Expects FY26 Adjusted EBITDA Loss of $30M-$35M

Backs FY26 adjusted EBITDA loss view $30M-$35M. "We also continue to expand our understanding of our AdrenaVerse epinephrine prodrug platform and the opportunity it presents," continued Daniel Barber. "Controlling the absorption and release of epinephrine allows us to target a variety of indications, especially in dermatological indications such as atopic dermatitis. The well-documented ability of epinephrine to lower histamine release through stabilizing mast cells while also downregulating key inflammatory components of atopic dermatitis creates the potential for a compelling product profile. Although AQST-108 is still in early-stage development, we are encouraged by the emerging data and plan on continuing to advance the program as we look towards 2027."

6/26 16:30

Aquestive Therapeutics Files to Sell 230,271 Shares of Common Stock

Aquestive Therapeutics files to sell 230,271 shares of common stock for holders

本页仅供研究参考,不构成投资建议。模型可能出错。过往表现不代表未来结果。

免费开始